Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019108 | 0.89 | PPARD (0.62) | PPARDPPARA | |
| SCHEMBL377558 | 0.88 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL391725 | 0.87 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL391757 | 0.87 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL10151581 | 0.87 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL13680132 | 0.87 | PPARD (0.58) | PPARDPPARA | |
| SCHEMBL7016508 | 0.85 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL12085303 | 0.85 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL7015286 | 0.84 | PPARD (0.56) | PPARDPPARA | |
| SCHEMBL14355027 | 0.82 | PPARD (0.54) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9724322-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9724322-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-08 | — | — | US | disclosed |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-8518997-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-20120122988-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-8106095-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20100069496-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069496-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7635718-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-7635718-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-2100877-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | Janssen Pharmaceutica, N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1667964-B1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122988-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20100069496-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.